Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity

D. Li, S. Brackenridge, LC. Walters, O. Swanson, K. Harlos, D. Rozbesky, DW. Cain, K. Wiehe, RM. Scearce, M. Barr, Z. Mu, R. Parks, M. Quastel, RJ. Edwards, Y. Wang, W. Rountree, KO. Saunders, G. Ferrari, P. Borrow, EY. Jones, SM. Alam, ML....

. 2022 ; 5 (1) : 271. [pub] 20220328

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019112

Grantová podpora
UM1 AI126619 NIAID NIH HHS - United States
UM1 AI164567 NIAID NIH HHS - United States
OPP1108533 Bill and Melinda Gates Foundation

The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A+ NK cell line. Structural analysis reveal that 3H4 acts by preventing CD94/NKG2A docking on HLA-E-VL9. Upon in vitro maturation, an affinity-optimized IgG form of 3H4 showes enhanced NK killing of HLA-E-VL9-expressing cells. HLA-E-VL9-specific IgM antibodies similar in function to 3H4 are also isolated from naïve B cells of cytomegalovirus (CMV)-negative, healthy humans. Thus, HLA-E-VL9-targeting mouse and human antibodies isolated from the naïve B cell antibody pool have the capacity to enhance NK cell cytotoxicity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019112
003      
CZ-PrNML
005      
20220804135349.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s42003-022-03183-5 $2 doi
035    __
$a (PubMed)35347236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Li, Dapeng $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA $1 https://orcid.org/0000000281315914
245    10
$a Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity / $c D. Li, S. Brackenridge, LC. Walters, O. Swanson, K. Harlos, D. Rozbesky, DW. Cain, K. Wiehe, RM. Scearce, M. Barr, Z. Mu, R. Parks, M. Quastel, RJ. Edwards, Y. Wang, W. Rountree, KO. Saunders, G. Ferrari, P. Borrow, EY. Jones, SM. Alam, ML. Azoitei, GM. Gillespie, AJ. McMichael, BF. Haynes
520    9_
$a The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A+ NK cell line. Structural analysis reveal that 3H4 acts by preventing CD94/NKG2A docking on HLA-E-VL9. Upon in vitro maturation, an affinity-optimized IgG form of 3H4 showes enhanced NK killing of HLA-E-VL9-expressing cells. HLA-E-VL9-specific IgM antibodies similar in function to 3H4 are also isolated from naïve B cells of cytomegalovirus (CMV)-negative, healthy humans. Thus, HLA-E-VL9-targeting mouse and human antibodies isolated from the naïve B cell antibody pool have the capacity to enhance NK cell cytotoxicity.
650    _2
$a zvířata $7 D000818
650    12
$a cytotoxicita imunologická $7 D003602
650    _2
$a HLA antigeny $7 D006680
650    12
$a MHC antigeny I. třídy $x genetika $7 D015395
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny $x metabolismus $7 D007136
650    _2
$a buňky NK $7 D007694
650    _2
$a myši $7 D051379
650    _2
$a peptidy $x metabolismus $7 D010455
650    _2
$a proteiny - lokalizační signály $7 D021382
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brackenridge, Simon $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK $1 https://orcid.org/0000000205877560
700    1_
$a Walters, Lucy C $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK
700    1_
$a Swanson, Olivia $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $1 https://orcid.org/0000000181628358
700    1_
$a Harlos, Karl $u Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK $1 https://orcid.org/0000000272664354
700    1_
$a Rozbesky, Daniel $u Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK $u Department of Cell Biology, Charles University, Prague, 12800, Czech Republic
700    1_
$a Cain, Derek W $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Wiehe, Kevin $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Scearce, Richard M $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Barr, Maggie $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Mu, Zekun $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $1 https://orcid.org/0000000340938346
700    1_
$a Parks, Robert $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Quastel, Max $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK $1 https://orcid.org/0000000165514713
700    1_
$a Edwards, Robert J $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA $1 https://orcid.org/0000000344461194
700    1_
$a Wang, Yunfei $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Rountree, Wes $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Saunders, Kevin O $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA $1 https://orcid.org/0000000173997954
700    1_
$a Ferrari, Guido $u Department of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Borrow, Persephone $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK $1 https://orcid.org/0000000238779780
700    1_
$a Jones, E Yvonne $u Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK $1 https://orcid.org/0000000238341893
700    1_
$a Alam, S Munir $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA
700    1_
$a Azoitei, Mihai L $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. mihai.azoitei@duke.edu $u Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA. mihai.azoitei@duke.edu $1 https://orcid.org/0000000240801350
700    1_
$a Gillespie, Geraldine M $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. geraldine.gillespie@ndm.ox.ac.uk $1 https://orcid.org/000000021075870X
700    1_
$a McMichael, Andrew J $u Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. andrew.mcmichael@ndm.ox.ac.uk $1 https://orcid.org/0000000291017478 $7 xx0246787
700    1_
$a Haynes, Barton F $u Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. barton.haynes@duke.edu $u Department of Immunology, Duke University School of Medicine, Durham, NC, 27710, USA. barton.haynes@duke.edu $1 https://orcid.org/0000000276439023 $7 nlk20050163552
773    0_
$w MED00197237 $t Communications biology $x 2399-3642 $g Roč. 5, č. 1 (2022), s. 271
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35347236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135343 $b ABA008
999    __
$a ok $b bmc $g 1822634 $s 1170355
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 5 $c 1 $d 271 $e 20220328 $i 2399-3642 $m Communications biology $n Commun Biol $x MED00197237
GRA    __
$a UM1 AI126619 $p NIAID NIH HHS $2 United States
GRA    __
$a UM1 AI164567 $p NIAID NIH HHS $2 United States
GRA    __
$a OPP1108533 $p Bill and Melinda Gates Foundation
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace